This paper investigates Raman spectroscopy as a quick and reliable method to quantify the alpha (α) and gamma (γ) polymorphic forms of indomethacin compared to differential scanning calorimetry (DSC). Binary mixtures with different ratios of α and γ indomethacin were prepared and analyzed by Raman and DSC. The Raman method was found to be more reliable and superior compared to DSC. The partial conversion of the alpha to gamma polymorphic form during the DSC measurement was the major limitation for the use of full DSC as a quantitative method and resulted in difference between the calculated and measured enthalpy of both polymorphic forms. 1. Introduction Polymorphism is a commonly encountered phenomenon in pharmaceutical formulations and final products. Scientists’ interest in understanding pharmaceutically relevant aspects of polymorphism have increased over the years, in particular the drugs’ different metastable polymorphic forms, the polymorphic forms dissolution rate, and their thermodynamic properties, as well as the in vivo drug kinetics [1–3]. The appearance or disappearance of a defined drug polymorphic form during manufacturing or storage is a major concern in drug process development [4–7]. Thus rapid and reliable quantification of polymorphic forms of active drug ingredients (API) is essential during drug manufacturing [8–10]. DSC monitors the heat changes associated with physical transformations; this includes transformation from (i) amorphous to crystalline form, (ii) crystalline drug to a different polymorph form, and (iii) crystalline drug to an amorphous solid-state mixture. Thus, DSC is routinely used to characterize amorphous systems, polymorphic changes studies, and in the quantification of the amorphous and crystalline contents in solid mixture [11–13]. The quantity of one polymorphic form can be estimated by either heat of crystallization or heat of fusion [14, 15]. A major limitation in using DSC as a quantitative tool is the relative thermodynamic stability of the polymorphic forms. The interconversion of the polymorphic forms during the thermograms collection is the chief obstacle in the extensive use of DSC as a quantitative tool. Experimental modifications and validation may be required to overcome this potential problem. IR has widely been used in quantitative and qualitative analysis of drugs in solid-state mixtures and blends. Although near infrared (IR) has been a dominating technique for the past decades, there is a significant increase in using Raman spectroscopy in solid- and liquid-state quantitative analysis [16].
References
[1]
H. G. Brittain, “Polymorphism and solvatomorphism 2005,” Journal of Pharmaceutical Sciences, vol. 96, no. 4, pp. 705–728, 2007.
[2]
R. W. Lancaster, P. G. Karamertzanis, A. T. Hulme, D. A. Tocher, T. C. Lewis, and S. L. Price, “The polymorphism of progesterone: stabilization of a “disappearing” polymorph by co-crystallization,” Journal of Pharmaceutical Sciences, vol. 96, no. 12, pp. 3419–3431, 2007.
[3]
J. Bauer, S. Spanton, R. Henry et al., “Ritonavir: an extraordinary example of conformational polymorphism,” Pharmaceutical Research, vol. 18, no. 6, pp. 859–866, 2001.
[4]
J. E. Patterson, M. B. James, A. H. Forster, R. W. Lancaster, J. M. Butler, and T. Rades, “The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds,” Journal of Pharmaceutical Sciences, vol. 94, no. 9, pp. 1998–2012, 2005.
[5]
A. K. Tiwary, “Modification of crystal habit and its role in dosage form performance,” Drug Development and Industrial Pharmacy, vol. 27, no. 7, pp. 699–709, 2001.
[6]
N. Sandler, J. Rantanen, J. Hein?m?ki, M. R?mer, M. Marvola, and J. Yliruusi, “Pellet manufacturing by extrusion-spheronization using process analytical technology,” AAPS PharmSciTech, vol. 6, no. 2, article 26, pp. E174–E183, 2005.
[7]
S. Airaksinen, M. Karjalainen, E. R?s?nen, J. Rantanen, and J. Yliruusi, “Comparison of the effects of two drying methods on polymorphism of theophylline,” International Journal of Pharmaceutics, vol. 276, no. 1-2, pp. 129–141, 2004.
[8]
M. E. Auer, U. J. Griesser, and J. Sawatzki, “Qualitative and quantitative study of polymorphic forms in drug formulations by near infrared FT-Raman spectroscopy,” Journal of Molecular Structure, vol. 661-662, no. 1–3, pp. 307–317, 2003.
[9]
K. P?ll?nen, A. H?kkinen, S. Reinikainen et al., “IR spectroscopy together with multivariate data analysis as a process analytical tool for in-line monitoring of crystallization process and solid-state analysis of crystalline product,” Journal of Pharmaceutical and Biomedical Analysis, vol. 38, no. 2, pp. 275–284, 2005.
[10]
M. Trifkovic, S. Rohani, and M. Mirmehrabi, “Polymorphic generation through solvent selection: ranitidine hydrochloride,” Organic Process Research and Development, vol. 11, no. 1, pp. 138–143, 2007.
[11]
R. Lefort, A. De Gusseme, J. F. Willart, F. Danède, and M. Descamps, “Solid state NMR and DSC methods for quantifying the amorphous content in solid dosage forms: an application to ball-milling of trehalose,” International Journal of Pharmaceutics, vol. 280, no. 1-2, pp. 209–219, 2004.
[12]
H. Ahmed, G. Buckton, and D. A. Rawlins, “The use of isothermal microcalorimetry in the study of small degrees of amorphous content of a hydrophobic powder,” International Journal of Pharmaceutics, vol. 130, no. 2, pp. 195–201, 1996.
[13]
Z. Német, G. C. Kis, G. Pokol, and A. Demeter, “Quantitative determination of famotidine polymorphs: X-ray powder diffractometric and Raman spectrometric study,” Journal of Pharmaceutical and Biomedical Analysis, vol. 49, no. 2, pp. 338–346, 2009.
[14]
E. M. Phillips, “An approach to estimate the amorphous content of pharmaceutical powders using calorimetry with no calibration standards,” International Journal of Pharmaceutics, vol. 149, no. 2, pp. 267–271, 1997.
[15]
B. Shah, V. K. Kakumanu, and A. K. Bansal, “Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids,” Journal of Pharmaceutical Sciences, vol. 95, no. 8, pp. 1641–1665, 2006.
[16]
A. Heinz, M. Savolainen, T. Rades, and C. J. Strachan, “Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy,” European Journal of Pharmaceutical Sciences, vol. 32, no. 3, pp. 182–192, 2007.
[17]
Y. Hu, H. Wikstr?m, S. R. Byrn, and L. S. Taylor, “Analysis of the effect of particle size on polymorphic quantitation by Raman spectroscopy,” Applied Spectroscopy, vol. 60, no. 9, pp. 977–984, 2006.
[18]
A. L. Enculescu and J. R. Steiginga, “Raman spectroscopy—a powerful tool for non-routine analysis of pharmaceuticals,” American Pharmaceutical Review, vol. 5, no. 1, pp. 81–88, 2002.
[19]
A. W. Newman and S. R. Byrn, “Solid-state analysis of the active pharmaceutical ingredient in drug products,” Drug Discovery Today, vol. 8, no. 19, pp. 898–905, 2003.
[20]
N. Kaneniwa, M. Otsuka, and T. Hayashi, “Physicochemical characterization of indomethacin polymorphs and the transformation kinetics in ethanol,” Chemical and Pharmaceutical Bulletin, vol. 33, no. 8, pp. 3447–3455, 1985.
[21]
L. S. Taylor and G. Zografi, “Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions,” Pharmaceutical Research, vol. 14, no. 12, pp. 1691–1698, 1997.
[22]
X. Pan, T. Julian, and L. Augsburger, “Increasing the dissolution rate of a low-solubility drug through a crystalline-amorphous transition: a case study with indomethicin,” Drug Development and Industrial Pharmacy, vol. 34, no. 2, pp. 221–231, 2008.
[23]
J. Johansson, S. Pettersson, and S. Folestad, “Characterization of different laser irradiation methods for quantitative Raman tablet assessment,” Journal of Pharmaceutical and Biomedical Analysis, vol. 39, no. 3-4, pp. 510–516, 2005.
[24]
M. E. Auer, U. J. Griesser, and J. Sawatzki, “Qualitative and quantitative study of polymorphic forms in drug formulations by near infrared FT-Raman spectroscopy,” Journal of Molecular Structure, vol. 661-662, no. 1–3, pp. 307–317, 2003.
[25]
S. Virtanen, O. Antikainen, and J. Yliruusi, “Determination of the crushing strength of intact tablets using Raman spectroscopy,” International Journal of Pharmaceutics, vol. 360, no. 1-2, pp. 40–46, 2008.
[26]
E. Atef, H. Chauhan, M. Ceresia, and C. Pidgeon, “Using Raman spectroscopy in tablet moisture surface analysis: tablet surface markers,” Journal of Pharmaceutical and Biomedical Analysis, vol. 53, no. 4, pp. 852–859, 2010.
[27]
C. McGregor and E. Bines, “The use of high-speed differential scanning calorimetry (Hyper-DSC) in the study of pharmaceutical polymorphs,” International Journal of Pharmaceutics, vol. 350, no. 1-2, pp. 48–52, 2008.
[28]
C. McGregor, M. H. Saunders, G. Buckton, and R. D. Saklatvala, “The use of high-speed differential scanning calorimetry (Hyper-DSC) to study the thermal properties of carbamazepine polymorphs,” Thermochimica Acta, vol. 417, no. 2, pp. 231–237, 2004.